Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial

Abstract

This investigator-initiated, phase 2, single-arm trial primarily assessed the efficacy of G47∆, a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult patients with residual or recurrent, supratentorial glioblastoma after radiation therapy and temozolomide (UMIN-CTR Clinical Trial Registry UMIN000015995). G47Δ was administered intratumorally and repeatedly for up to six doses. The primary endpoint of 1-yr survival rate after G47∆ initiation was 84.2% (95% confidence interval, 60.4–96.6; 16 of 19). The prespecified endpoint was met and the trial was terminated early. Regarding secondary endpoints, the median overall survival was 20.2 (16.8–23.6) months after G47∆ initiation and 28.8 (20.1–37.5) months from the initial surgery. The most common G47∆-related adverse event was fever (17 of 19) followed by vomiting, nausea, lymphocytopenia and leukopenia. On magnetic resonance imaging, enlargement of and contrast-enhancement clearing within the target lesion repeatedly occurred after each G47∆ administration, which was characteristic to this therapy. Thus, the best overall response in 2 yr was partial response in one patient and stable disease in 18 patients. Biopsies revealed increasing numbers of tumor-infiltrating CD4 + /CD8 + lymphocytes and persistent low numbers of Foxp3 + cells. This study showed a survival benefit and good safety profile, which led to the approval of G47∆ as the first oncolytic virus product in Japan.

References 47

1. 1.

   Stupp R, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318:2306-2316.

   Not in our library10.1001/jama.2017.18718

2. 2.

   Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl Acad. Sci. USA. 2001;98:6396-6401.

   Not in our library10.1073/pnas.101136398

3. 3.

   Ma W, He H, Wang H. Oncolytic herpes simplex virus and immunotherapy. BMC Immunol. 2018;19:40.

   Not in our library10.1186/s12865-018-0281-9

4. 4.

   Carson J, Haddad D, Bressman M, Fong Y. Oncolytic herpes simplex virus 1 (HSV-1) vectors: increasing treatment efficacy and range through strategic virus design. Drugs Future. 2010;35:183-195.

   Not in our library10.1358/dof.2010.35.3.1470166

5. 5.
   A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma · 2022

   No notice
6. 6.

   Ikegami N, et al. Japanese universal health coverage: evolution, achievements, and challenges. Lancet. 2011;378:1106-1115.

   Not in our library10.1016/s0140-6736(11)60828-3

7. 7.

   Koga T, et al. Extended field stereotactic radiosurgery for recurrent glioblastoma. Cancer. 2012;118:4193-4200.

   Not in our library10.1002/cncr.27372

8. 8.

   Ballman KV, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007;9:29-38.

   Not in our library10.1215/15228517-2006-025

9. 9.

   Wick A, et al. Rechallenge with temozolomide in patients with recurrent gliomas. J. Neurol. 2009;256:734-741.

   Not in our library10.1007/s00415-009-5006-9

10. 10.

    Friedman HS, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009;27:4733-4740.

    Not in our library10.1200/jco.2008.19.8721

11. 11.

    Roy S, Lahiri D, Maji T, Biswas J. Recurrent glioblastoma: where we stand. South Asian J. Cancer. 2015;4:163-173.

    Not in our library10.4103/2278-330x.175953

12. 12.

    Brahm CG, et al. The current status of immune checkpoint inhibitors in neuro-oncology: a systematic review. Cancers (Basel). 2020;12:586.

    Not in our library10.3390/cancers12030586

13. 13.

    Stupp R, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur. J. Cancer. 2012;48:2192-2202.

    Not in our library10.1016/j.ejca.2012.04.011

14. 14.

    Mandel JJ, et al. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J. Neurooncol. 2016;129:147-154.

    Not in our library10.1007/s11060-016-2157-2

15. 15.

    Westphal M, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79-88.

    Not in our library10.1093/neuonc/5.2.79

16. 16.

    Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir. (Wien). 2006;148:269-275; discussion 275.

    Not in our library10.1007/s00701-005-0707-z

17. 17.

    De Bonis P, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir. (Wien). 2012;154:1371-1378.

    Not in our library10.1007/s00701-012-1413-2

18. 18.

    Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231-1251.

    Not in our library10.1093/neuonc/noab106

19. 19.

    Li Y, Ali S, Clarke J, Cha S. Bevacizumab in recurrent glioma: patterns of treatment failure and implications. Brain Tumor Res. Treat. 2017;5:1-9.

    Not in our library10.14791/btrt.2017.5.1.1

20. 20.

    Chahlavi A, Rabkin SD, Todo T, Sundaresan P, Martuza RL. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 1999;6:1751-1758.

    Not in our library10.1038/sj.gt.3301003

21. 21.

    Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603-2615.

    Not in our library10.1056/nejmoa2034577

22. 22.

    Dario A, Tomei G. The safety of the temozolomide in patients with malignant glioma. Curr. Drug Saf. 2006;1:205-222.

    Not in our library10.2174/157488606776930535

23. 23.
    The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights · 2011

    No notice
24. 24.

    Desjardins A, et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 2018;379:150-161.

    Not in our library10.1056/nejmoa1716435

25. 25.

    Markert JM, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000;7:867-874.

    Not in our library10.1038/sj.gt.3301205

26. 26.

    Markert JM, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM. Mol. Ther. 2009;17:199-207.

    Not in our library10.1038/mt.2008.228

27. 27.

    Markert JM, et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol. Ther. 2014;22:1048-1055.

    Not in our library10.1038/mt.2014.22

28. 28.

    Todo T, Rabkin SD, Chahlavi A, Martuza RL. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum. Gene Ther. 1999;10:2869-2878.

    Not in our library10.1089/10430349950016591

29. 29.

    Van Gool F, et al. A mutation in the transcription factor Foxp3 drives T helper 2 effector function in regulatory T cells. Immunity. 2019;50:362-377.e366.

    Not in our library10.1016/j.immuni.2018.12.016

30. 30.
    Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma · 2019

    No notice
31. 31.

    Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res. 2007;67:440-444.

    Not in our library10.1158/0008-5472.can-06-3145

32. 32.

    Carpenter AB, Carpenter AM, Aiken R, Hanft S. Oncolytic virus in gliomas: a review of human clinical investigations. Ann. Oncol. 2021;32:968-982.

    Not in our library10.1016/j.annonc.2021.03.197

33. 33.

    Lang FF, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J. Clin. Oncol. 2018;36:1419-1427.

    Not in our library10.1200/jco.2017.75.8219

34. 34.

    Friedman GK, et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N. Engl. J. Med. 2021;384:1613-1622.

    Not in our library10.1056/nejmoa2024947

35. 35.

    Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373-1379.

    Not in our library10.1111/cas.13027

36. 36.

    Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T. Oncolytic herpes simplex virus vector G47Δ in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin. Cancer Res. 2005;11:7886-7890.

    Not in our library10.1158/1078-0432.ccr-05-1090

37. 37.
    Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer · 2020

    Not checked
38. 38.
    Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency Ablation · 2020

    Not checked
39. 39.

    Liu R, Martuza RL, Rabkin SD. Intracarotid delivery of oncolytic HSV vector G47∆ to metastatic breast cancer in the brain. Gene Ther. 2005;12:647-654.

    Not in our library10.1038/sj.gt.3302445

40. 40.

    Uchihashi T, et al. Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis. Mol. Ther. Oncolytics. 2021;22:388-398.

    Not in our library10.1016/j.omto.2021.06.008

Cited by papers we hold 10

• Glioblastoma at the crossroads: current understanding and future therapeutic horizons · 2025
  No notice
• Glioblastoma Therapy: Past, Present and Future · 2024
  No notice
• Exploring treatment options in cancer: tumor treatment strategies · 2024
  No notice
• Immunotherapy for glioblastoma: current state, challenges, and future perspectives · 2024
  No notice
• Immunotherapy: a promising approach for glioma treatment · 2023
  No notice
• Oncolytic virotherapy: basic principles, recent advances and future directions · 2023
  No notice
• Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial · 2023
  Corrected
• Recurrent Glioblastoma: A Review of the Treatment Options · 2023
  No notice
• Clinical trial links oncolytic immunoactivation to survival in glioblastoma · 2023
  No notice
• Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases · 2023
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.